<h4>Background</h4>Anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibody therapy has been approved as second-line treatment for advanced non-small-cell lung cancer (NSCLC). The gene discussed is CD274; the disease is non-small cell lung carcinoma.